Tokyo, Japan

Takuya Yokosaka

USPTO Granted Patents = 2 

 

 

Average Co-Inventor Count = 10.6

ph-index = 1


Company Filing History:


Years Active: 2018-2021

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Takuya Yokosaka: Innovator in Pharmaceutical Chemistry

Introduction

Takuya Yokosaka, based in Tokyo, Japan, is a prominent inventor known for his significant contributions to pharmaceutical chemistry. With a strong focus on developing innovative compounds, Yokosaka holds two patents that showcase his dedication to advancing medical science.

Latest Patents

Yokosaka's latest patents involve the creation of Pyrido[3, 4-d]pyrimidine derivatives and their pharmaceutically acceptable salts. The primary goal of these inventions is to provide compounds exhibiting excellent CDK4/6 inhibitory activity, which is crucial for cancer treatment. Each patent introduces a compound represented by a specific formula, emphasizing its potential therapeutic benefits in modern medicine.

Career Highlights

Takuya Yokosaka is a key member of Teijin Pharma Limited, where he applies his expertise in drug development and chemical synthesis to push the boundaries of what is possible in the pharmaceutical industry. His innovative work contributes not only to the company’s growth but also impacts overall healthcare solutions.

Collaborations

Throughout his career, Yokosaka has collaborated with talented professionals such as Tsuyoshi Mizuno and Tomohiro Shimada. These partnerships have facilitated a thriving environment for innovation and have strengthened their collective contributions to the field of pharmaceutical research.

Conclusion

Takuya Yokosaka is a visionary inventor whose work continues to shape the future of medicinal chemistry. By focusing on effective CDK4/6 inhibitors, he has positively impacted therapeutic development, demonstrating the power of innovation in addressing critical healthcare challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…